Investigational drug · Phase 2
TQC3721
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pulmonary Disease, Chronic Obstructive.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
8
Any phase or sponsor naming "TQC3721"
First trial start
2025
Dec 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQC3721", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Disease, Chronic Obstructive
Approved drugs for the same conditions: Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "TQC3721" as an intervention, largest first.
- Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07464587 · 800 participants (planned) · Start Apr 14, 2026 · Primary completion Feb 2027
Drug: TQC3721 Suspension for Inhalation · For: Chronic Obstructive Pulmonary Disease
Sites: Chizhou, China; Hefei, China; Chongqing, China · 54 sites in all
- Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07147946 · 666 participants (planned) · Start Sep 2025 · Primary completion Mar 2027
Drug: TQC3721 Suspension for inhalation; Placebo of TQC3721 Suspension for Inhalation · For: Chronic Obstructive Pulmonary Disease
Sites: Bozhou, China; Chizhou, China; Hefei, China · 76 sites in all
- A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06527144 · 240 participants · Start Sep 14, 2024 · Primary completion Jan 16, 2025
Drug: 3mg TQC3721 Suspension for Inhalation; 6mg TQC3721 Suspension for Inhalation and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Fuyang, China; Chongqing, China; Xiamen, China · 28 sites in all
- A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation PowderPivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07252908 · 195 participants · Start Dec 22, 2025 · Primary completion Apr 28, 2026
Drug: TQC3721 inhalation powder; Placebo for TQC3721 inhalation powder · For: Pulmonary Disease, Chronic Obstructive
Sites: Chongqing, China; Guangzhou, China; Jiangmen, China · 29 sites in all
- A Clinical Trial of TQC3721 Suspension for InhalationPivotal-lookingStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05051930 · 114 participants (planned) · Start Oct 18, 2021 · Primary completion Oct 31, 2022
Drug: TQC3721 suspension for inhalation; TQC3721 suspension placebo for inhalation · For: Chronic Obstructive Pulmonary Disease
Sites: Chengdu, China
- A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06748079 · 113 participants · Start Dec 3, 2024 · Primary completion Aug 7, 2026
Drug: TQC3721 inhalation powder; Placebo for TQC3721 inhalation powder and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chengdu, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05987371 · 75 participants · Start Aug 23, 2023 · Primary completion Jan 16, 2024
Drug: TQC3721 suspension for inhalation; TQC3721 matching placebo for inhalation and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Guangzhou, China; Zhanjiang, China; Wuhan, China · 11 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05292196 · 59 participants · Start May 20, 2022 · Primary completion Jan 11, 2023
Drug: TQC3721 suspension for inhalation; TQC3721 suspension placebo for inhalation · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Chongqing, China; Lanzhou, China; Zhanjiang, China · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics and pharmacodynamics of TQC3721, an innovative, dual PDE3 and PDE4 inhibitor, in healthy subjects and patients with chronic obstructive pulmonary disease: Randomised, double-blind, placebo-controlled phase I and IIa clinical trials.
He L, Yang L, Li W, et al. · Br J Pharmacol 2026
- TQC3721: Expanding the Role of Dual Phosphodiesterase 3/4 Inhibition in COPD Management.
Cazzola M, Matera MG · Chest 2026
- Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients With COPD in China (PACER-II): A Phase 2, Multicenter, Randomized, Double-Anonymized, Placebo-Controlled Trial.
He LX, Yang L, Xiao ZK, et al. · Chest 2026
Also in development for Pulmonary Disease, Chronic Obstructive
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- TQC3721 forPhase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Obstructive Pulmonary Disease, Pulmonary Disease, Chronic Obstructive
- GSK3862995BPhase 22 trials
GSK · Bronchiectasis, Pulmonary Disease, Chronic Obstructive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.